Shouyao Holdings Beijing Co. Ltd. Class ASSE: 688197

"SHOUYAO HOLDINGS CO., LTD."Announcement on the Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Fourth-generation ALK Inhibitor SY-12321

Jul 17, 2026 · Issued by Shouyao Holdings Beijing Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on the Voluntary Disclosure of Obtaining Drug Clinical Trial Approval Notice for the Fourth-generation ALK Inhibitor SY-12321

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Shouyao Holdings Beijing Co. Ltd. Class A

"SHOUYAO HOLDINGS CO., LTD."Announcement on Completion of Industrial and Commercial Registration Changes and Renewal of Business LicenseJul 7
Announcement on Resolutions of the 2025 Annual General MeetingJun 27
Announcement on Voluntary Disclosure of Approval of ALK Inhibitor Conteltinib Granules (Shouyaoze®) for Marketing by the National Medical Products AdministrationJun 12
Announcement on Resolutions of the 14th Meeting of the 2nd Board of DirectorsJun 6

All Shouyao Holdings Beijing Co. Ltd. Class A news releases